Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC known ✓ | P12931 | 17/20 | 0.98 |
| ▸ | ABL1 known ✓ | P00519 | 9/20 | 0.98 |
| ▸ | PDGFRB known ✓ | P09619 | 7/20 | 0.98 |
| ▸ | KDR known ✓ | P35968 | 5/20 | 0.98 |
| ▸ | LCK known ✓ | P06239 | 4/20 | 0.98 |
| ▸ | RET known ✓ | P07949 | 3/20 | 0.98 |
| ▸ | BCR known ✓ | P11274 | 2/20 | 0.98 |
| ▸ | PRKD3 known ✓ | O94806 | 1/20 | 0.98 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.71 |
| ▸ | FGFR1 known ✓ | P11362 | 1/20 | 0.71 |
| ▸ | YES1 | P07947 | 7/20 | 0.98 |
| ▸ | EPHB4 | P54760 | 5/20 | 0.98 |
| ▸ | GAK | O14976 | 2/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.98 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.98 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.98 |
| ▸ | ABL2 | P42684 | 2/20 | 0.98 |
| ▸ | EPHA4 | P54764 | 2/20 | 0.98 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.98 |
| ▸ | CIT | O14578 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366448 | 0.99 | SRC (1.00) | SRCABL1YES1PDGFRBKDR | |
| SCHEMBL4269019 | 0.99 | SRC (1.00) | SRCABL1YES1PDGFRBKDR | |
| SCHEMBL15095269 | 0.91 | SRC (0.86) | SRCABL1YES1PDGFRBKDR | |
| SCHEMBL4272173 | 0.91 | SRC (1.00) | SRCABL1YES1PDGFRBKDR | |
| SCHEMBL4265021 | 0.90 | SRC (1.00) | SRCABL1YES1PDGFRBKDR | |
| SCHEMBL4275780 | 0.89 | SRC (1.00) | SRCABL1YES1PDGFRBKDR | |
| SCHEMBL4272203 | 0.88 | SRC (1.00) | SRCABL1YES1PDGFRBKDR | |
| SCHEMBL4264210 | 0.88 | SRC (0.85) | SRCABL1YES1PDGFRBKDR | |
| SCHEMBL12198200 | 0.88 | SRC (0.80) | SRCABL1YES1PDGFRBKDR | |
| SCHEMBL231130 | 0.87 | SRC (0.78) | SRCABL1YES1PDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3954436-B1 | METHOD FOR PRODUCING BIOTISSUE-LIKE STRUCTURE | ORIZURU THERAPEUTICS INC (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20250170090-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT | ONQUALITY PHARMACEUTICALS CHINA LTD (CN) | 2025-05-29 | — | — | US | disclosed |
| US-12268715-B2 | Method for producing biological tissue-like structure | Orizuru Therapeutics, Inc. (JP) | 2025-04-08 | — | — | US | disclosed |
| EP-4470565-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT | OnQuality Pharmaceuticals China Ltd. (CN) | 2024-12-04 | — | — | EP | disclosed |
| CN-112867787-B | Insulin producing cells | 千纸鹤治疗公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240318141-A1 | MATURATION AGENT | Orizuru Therapeutics, Inc. (JP) | 2024-09-26 | — | — | US | disclosed |
| CN-112313327-B | Proliferation inhibitors | 千纸鹤治疗公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4293105-A1 | MATURATION AGENT | Orizuru Therapeutics, Inc. (JP) | 2023-12-20 | — | — | EP | disclosed |
| WO-2022172960-A1 | MATURATION AGENT | オリヅルセラピューティクス株式会社 | 2022-08-18 | — | — | WO | disclosed |
| US-20220168357-A1 | METHOD FOR PRODUCING BIOLOGICAL TISSUE-LIKE STRUCTURE | Orizuru Therapeutics, Inc. (JP) | 2022-06-02 | — | — | US | disclosed |
| EP-3812456-A1 | GROWTH INHIBITOR | Kyoto University (JP) | 2021-04-28 | — | — | EP | disclosed |
| EP-1809614-B1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8481536-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2543376-A1 | Benzotriazine inhibitors of kinases | Targegen, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | TARGEGEN, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7456176-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1809614-A2 | BENZOTRIAZINE INHIBITORS OF KINASES | Targegen, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005096784-A2 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | SRC, CAMK4, CAMK2G | SRC 1/4885ABL1 15/4885PDGFRB 221/4885 |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | SRC, CAMK4, CAMK2G | SRC 1/4885ABL1 15/4885PDGFRB 221/4885 |
| US-20250170090-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT | VHL, SLC10A1, NNMT | SRC 2415/4885ABL1 2942/4885PDGFRB 4796/4885 |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | SRC, CAMK4, CAMK2G | SRC 1/4885ABL1 15/4885PDGFRB 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.